Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Improved Outcome of Relapsed/Refractory B-Cell Lymphomas Treated in Phase I Trials with T-Cell Engaging Bispecific Antibodies: A Single Center Experience

Monica Rondi, Silvia Ferrari, Anna Maria Barbui, Andrea Rossi, Chiara Pavoni, Anna Grassi, Federico Lussana, Alessandro Rambaldi, Giuseppe Gritti

Blood (2023) 142 (Supplement 1): 2331.

https://doi.org/10.1182/blood-2023-189911

Published: 2023

Journal Articles

Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma

Armando Santoro, Alison J. Moskowitz, Silvia Ferrari, Carmelo Carlo-Stella, Julie Lisano, Stephen Francis, Rachael Wen, Alev Akyol, Kerry J. Savage

Blood (2023) 141 (22): 2780–2783.

https://doi.org/10.1182/blood.2022017951

Published: 2023

Includes: Supplemental data

Journal Articles

Association of Immune Dynamics and Treatment Outcome in Patients (pts) with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) Treated with the Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent CC-99282

Soraya Carrancio, Wen-Chi Chou, Alberto Risueño, Carla Guarinos, Gonzalo Lopez, Jean-Marie Michot, Loretta J. Nastoupil, Julio Chavez, Cecilia Carpio, Silvia Ferrari, Tatyana A. Feldman, Daniel Morillo Giles, Antonio Pinto, Danielle Greenawalt, Daniel W. Pierce, Michael Pourdehnad

Blood (2022) 140 (Supplement 1): 6455–6457.

https://doi.org/10.1182/blood-2022-159585

Published: 2022

Journal Articles

Efficacy and Safety of Danazol in Patients with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms: A Multicenter Observational Study

Alessandro Bosi, Bruno Fattizzo, Lorenzo Rizzo, Silvia Ferrari, Federico Lussana, Lorenza Maria Borin, Andrea Castelli, Paola Bianchi, Wilma Barcellini, Roberto Cairoli, Alfredo Molteni, Marta Riva

Blood (2022) 140 (Supplement 1): 6925–6926.

https://doi.org/10.1182/blood-2022-157430

Published: 2022

Journal Articles

Carcik-CD19 Cells Expand In Vivo Toward a CD8 + Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response

Blood (2022) 140 (Supplement 1): 10339–10340.

https://doi.org/10.1182/blood-2022-166788

Published: 2022

Journal Articles

Immune Reconstitution Following Infusion of Autologous Blinatumomab Expanded T-Cells (BET) in CD20+ Indolent Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Receiving Front-Line Treatment with Fludarabine-Cyclophosphamide-Rituximab or Bendamustine-Rituximab

Giuseppe Gritti, Federico Lussana, Silvia Ferrari, Anna Maria Barbui, Francesco Landi, Giulia Quaresmini, Gianmaria Borleri, Muriel Paganessi, Chiara Pavoni, Elisa Gotti, Chiara Capelli, Josee Golay, Martino Introna, Alessandro Rambaldi

Blood (2022) 140 (Supplement 1): 10325–10326.

https://doi.org/10.1182/blood-2022-170120

Published: 2022

Journal Articles

Final Results of Phase I/II Study of Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed Post-HSCT

Blood (2022) 140 (Supplement 1): 4568–4569.

https://doi.org/10.1182/blood-2022-165448

Published: 2022

Journal Articles

Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Relapsed Post-HSCT

Blood (2021) 138 (Supplement 1): 472.

https://doi.org/10.1182/blood-2021-148703

Published: 2021

Journal Articles

Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study

Jean-Marie Michot, Julio C. Chavez, Cecilia Carpio, Silvia Ferrari, Tatyana A. Feldman, Daniel Morillo, John Kuruvilla, Antonio Pinto, Vincent Ribrag, Emmanuel Bachy, Tonia J Buchholz, Soraya Carrancio, Carla Guarinos, Fan Wu, Shaoyi Li, Poliana Patah, Michael Pourdehnad, Loretta Nastoupil

Blood (2021) 138 (Supplement 1): 3574.

https://doi.org/10.1182/blood-2021-147333

Published: 2021

Journal Articles

A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL)

Giuseppe Rossi, Henry Miles Prince, Constantine S. Tam, Matthew Ku, Catherine Thieblemont, Leslie L. Popplewell, Martin Wermke, Corinne Haioun, Nicole Wong Doo, Andreas Viardot, Andrés J M Ferreri, Silvia Ferrari, Hansen L. Wong, Priti Kadu, Gerhard Zugmaier, Yi Zeng, Alessandro Rambaldi

Blood (2021) 138 (Supplement 1): 2436.

https://doi.org/10.1182/blood-2021-152822

Published: 2021

Journal Articles

Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Mediastinal Gray Zone Lymphoma: Primary Efficacy and Safety Analysis of the Phase 2 CheckMate 436 Study

Armando Santoro, Alison J. Moskowitz, MD, Silvia Ferrari, MD, Carmelo Carlo-Stella, MD, Michelle A. Fanale, MD, Stephen Francis, Mariana Sacchi, MD, Kerry J. Savage, MDMSc

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-137653

Published: 2020

Journal Articles

Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141236

Published: 2020

Journal Articles

Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blood (2019) 134 (Supplement_1): 200.

https://doi.org/10.1182/blood-2019-125894

Published: 2019

Journal Articles

A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Tycel J. Phillips, MD, Gilles Salles, MD PhD, Daniel J. Landsburg, MD, Giuseppe Gritti, MD PhD, Krish Patel, MD, Herve Tilly, MD PhD, Catherine Thieblemont, MD PhD, William Townsend, MRCP,MDFRCPath, Silvia Ferrari, MD, Kate F. Stumpo, BA, Shilpi Katyayan, Cheryl Li, Harry Miao, MD, Igor Proscurshim, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5310.

https://doi.org/10.1182/blood-2019-125650

Published: 2019

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, MD, Bruce D. Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, MD, Uwe H Hahn, MD, Eliza A Hawkes, Cyrus Khan, MD, Izidore S. Lossos, MD, Gerardo Musuraca, MD PhD, Monica Tani, Umberto Vitolo, Sam Lung Sang Yuen, MBBS,FRCPA,FRACP, Aparna Raval, PhD, Mahesh R. Shivhare, PhD, Tina G Nielsen, MD PhD, Gila Sellam, PhD, Jeff P. Sharman, MD

Blood (2019) 134 (Supplement_1): 2874.

https://doi.org/10.1182/blood-2019-123368

Published: 2019

Journal Articles

Ofatumumab Is Active and Safe in Patients with Relapsed/Refractory Splenic Marginal Zone Lymphoma (SMZL): Results from the Interim Analysis of an Italian Multicenter Phase 2 Study (MORE trial)

Lydia Scarfo, MD, Silvia Ferrari, Annamaria Maria Frustaci, Monica Tani, Samantha Pozzi, MD, Eloise Scarano, Maria Colia, Pamela Ranghetti, Maurilio Ponzoni, MD, Paola Ronchi, MD, Andres JM Ferreri, MD, Paolo Ghia, MD PhD

Blood (2018) 132 (Supplement 1): 4162.

https://doi.org/10.1182/blood-2018-99-113875

Published: 2018

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, Bruce Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, Uwe Hahn, Eliza Hawkes, Cyrus Khan, Izidore S. Lossos, MD, Gerardo Musuraka, Monica Tani, Umberto Vitolo, Sam Yuen, Mikkel Z Oestergaard, Surya Chitra, Michael Wenger, Tina Nielsen, Gila Sellam, Jeff Sharman, MD

Blood (2018) 132 (Supplement 1): 2969.

https://doi.org/10.1182/blood-2018-99-116678

Published: 2018

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab and Bendamustine in Patients with Previously Untreated Follicular Lymphoma: An Interim Analysis

Anas Younes, MD, Burke M. John, Catherine S Diefenbach, Silvia Ferrari, Cyrus Kahn, Jeffrey P. Sharman, MD, Monica Tani, Chaitra S. Ujjani, MD, Umberto Vitolo, MD, Sam Yuen, Paul Woodard, Kirsten Mundt, Günter Fingerle-Rowson, Surya Chitra, Gila Sellam, Rodica Morariu-Zamfir, Michael Gilbertson

Blood (2017) 130 (Supplement 1): 481.

https://doi.org/10.1182/blood.V130.Suppl_1.481.481

Published: 2017

Journal Articles

Antibiotic Prophylaxis Revisited: The Impact of Fluoroquinolones on Epidemiology and on the Emergence of Resistant Strains in Acute Leukemia Patients. Results of a Prospective Study By the Rete Ematologia Lombarda (REL)

Chiara Cattaneo, MD, Patrizia Zappasodi, MD, Silvia Ferrari, MD, Francesca Pavesi, MD, Claudio Annaloro, MD, Cristina Skert, MD, Luisa Verga, MD, Elisabetta Todisco, MD, Andrea Ferrario, MD, Vittoria Saccà, Angela Passi, MD, Erika Borlenghi, MD, Matteo C Da Vià, MD, Valentina Mancini, Gabriella Mometto, Claudia Basilico, MD, Roberto Cairoli, Annamaria Nosari, Giuseppe Rossi, MD

Blood (2014) 124 (21): 4125.

https://doi.org/10.1182/blood.V124.21.4125.4125

Published: 2014

Journal Articles

Secondary Acute Myeloid Leukemia Is an Heterogeneous Subgroup of Elderly AML Where Patient’s Fitness Criteria and ELN Prognostic Stratification Can be Applied to Guide Treatment Decisions: An Analysis of 127 Patients By the Network Rete Ematologica Lombarda (REL)

Erika Borlenghi, MD, Chiara Pagani, MD, Claudia Basilico, MD, Massimo Bernardi, MD, Matteo Carrabba, MD, Nicola Fracchiolla, MD, Francesca Guidotti, MD, Laura Marbello, MD, Andrea Ferrario, MD, Silvia Ferrari, MD, Francesca Schieppati, MD, Daniela Dalceggio, MD, Giuseppe Rossi, MD

Blood (2014) 124 (21): 953.

https://doi.org/10.1182/blood.V124.21.953.953

Published: 2014

NARROW

Improved Outcome of Relapsed/Refractory B-Cell Lymphomas Treated in Phase I Trials with T-Cell Engaging Bispecific Antibodies: A Single Center Experience

Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma

Association of Immune Dynamics and Treatment Outcome in Patients (pts) with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) Treated with the Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent CC-99282

Efficacy and Safety of Danazol in Patients with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms: A Multicenter Observational Study

Carcik-CD19 Cells Expand In Vivo Toward a CD8 + Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response

Immune Reconstitution Following Infusion of Autologous Blinatumomab Expanded T-Cells (BET) in CD20+ Indolent Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Receiving Front-Line Treatment with Fludarabine-Cyclophosphamide-Rituximab or Bendamustine-Rituximab

Final Results of Phase I/II Study of Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed Post-HSCT

Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Relapsed Post-HSCT

Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study

A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL)

Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Mediastinal Gray Zone Lymphoma: Primary Efficacy and Safety Analysis of the Phase 2 CheckMate 436 Study

Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity

Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL)

A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Ofatumumab Is Active and Safe in Patients with Relapsed/Refractory Splenic Marginal Zone Lymphoma (SMZL): Results from the Interim Analysis of an Italian Multicenter Phase 2 Study (MORE trial)

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study

Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab and Bendamustine in Patients with Previously Untreated Follicular Lymphoma: An Interim Analysis

Antibiotic Prophylaxis Revisited: The Impact of Fluoroquinolones on Epidemiology and on the Emergence of Resistant Strains in Acute Leukemia Patients. Results of a Prospective Study By the Rete Ematologia Lombarda (REL)

Secondary Acute Myeloid Leukemia Is an Heterogeneous Subgroup of Elderly AML Where Patient’s Fitness Criteria and ELN Prognostic Stratification Can be Applied to Guide Treatment Decisions: An Analysis of 127 Patients By the Network Rete Ematologica Lombarda (REL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only